Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-11-16

AUTHORS

Heleen G. M. van Haalen, Marjolein Pompen, Klas Bergenheim, Phil McEwan, Rebecca Townsend, Marina Roudaut

ABSTRACT

Background and ObjectiveMany patients with type 2 diabetes mellitus (T2DM) on insulin therapy have inadequate glycaemic control. In such cases, Dutch guidelines recommend unlimited up-titration of insulin, yet in practice many patients never reach their glycaemic target. Clinical evidence shows that dapagliflozin—a highly selective sodium–glucose cotransporter 2 inhibitor—meets a need for these patients, i.e. by reducing glycated haemoglobin levels and bodyweight. We estimated the cost effectiveness and cost utility of adding dapagliflozin to insulin compared with not adding dapagliflozin in patients with T2DM who have inadequate glycaemic control while on insulin.MethodsThe cost effectiveness of dapagliflozin was estimated using the Cardiff Diabetes Model, using direct comparative efficacy data from a randomized placebo-controlled trial (ClinicalTrials.gov identifier NCT00673231). In this trial, up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk factor progression and the occurrence of future vascular events were estimated using the United Kingdom Prospective Diabetes Study 68 risk equations. Costs and utilities were derived from the literature. The analysis was conducted from the societal perspective, simulating the remaining lifetime of the patients.ResultsThe overall incidence of macro- and microvascular complications was lower, and life expectancy was greater (19.43 versus 19.35 life-years [LYs]) in patients receiving dapagliflozin than in those not receiving dapagliflozin. Patients in the dapagliflozin arm obtained an incremental benefit of 0.42 quality-adjusted life-years (QALYs). The lifetime incremental cost per patient in the dapagliflozin arm was €2,293, resulting in an incremental cost-effectiveness ratio of €27,779 per LY gained and an incremental cost–utility ratio of €5,502 per QALY gained. Sensitivity and scenario analyses showed that the results were insensitive to variations in modelling assumptions and input variables.ConclusionDapagliflozin in combination with insulin was estimated to be a cost-effective treatment option for patients with T2DM whose insulin treatment regimen does not provide adequate glycaemic control in a Dutch healthcare setting. More... »

PAGES

135-146

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-013-0155-0

DOI

http://dx.doi.org/10.1007/s40261-013-0155-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051450610

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24243529


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzhydryl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Netherlands", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Health Economics, AstraZeneca BV, P.O. Box 599, 2700 AN, Zoetermeer, The Netherlands", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Health Economics, AstraZeneca BV, P.O. Box 599, 2700 AN, Zoetermeer, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Haalen", 
        "givenName": "Heleen G. M.", 
        "id": "sg:person.07407076240.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07407076240.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb, Woerden, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.491222.e", 
          "name": [
            "Bristol-Myers Squibb, Woerden, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pompen", 
        "givenName": "Marjolein", 
        "id": "sg:person.0715210142.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715210142.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, M\u00f6lndal, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.418151.8", 
          "name": [
            "AstraZeneca, M\u00f6lndal, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bergenheim", 
        "givenName": "Klas", 
        "id": "sg:person.0700022153.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700022153.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre for Health Economics, Swansea University, Swansea, UK", 
          "id": "http://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "HEOR Ltd, Monmouth, UK", 
            "Centre for Health Economics, Swansea University, Swansea, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Brussels, Belgium", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AstraZeneca, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Townsend", 
        "givenName": "Rebecca", 
        "id": "sg:person.01270616201.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270616201.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcome Research, Bristol-Myers Squibb, Rueil-Malmaison, France", 
          "id": "http://www.grid.ac/institutes/grid.481843.2", 
          "name": [
            "Health Economics and Outcome Research, Bristol-Myers Squibb, Rueil-Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roudaut", 
        "givenName": "Marina", 
        "id": "sg:person.01365107104.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365107104.86"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1475-2840-7-24", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052715065", 
          "https://doi.org/10.1186/1475-2840-7-24"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10926-011-9317-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001967775", 
          "https://doi.org/10.1007/s10926-011-9317-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1478-7547-8-21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021046231", 
          "https://doi.org/10.1186/1478-7547-8-21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-010-0261-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020769088", 
          "https://doi.org/10.1007/s10198-010-0261-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11597060-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033801058", 
          "https://doi.org/10.2165/11597060-000000000-00000"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-11-16", 
    "datePublishedReg": "2013-11-16", 
    "description": "Background and ObjectiveMany patients with type\u00a02 diabetes mellitus (T2DM) on insulin therapy have inadequate glycaemic control. In such cases, Dutch guidelines recommend unlimited up-titration of insulin, yet in practice many patients never reach their glycaemic target. Clinical evidence shows that dapagliflozin\u2014a highly selective sodium\u2013glucose cotransporter\u00a02 inhibitor\u2014meets a need for these patients, i.e. by reducing glycated haemoglobin levels and bodyweight. We estimated the cost effectiveness and cost utility of adding dapagliflozin to insulin compared with not adding dapagliflozin in patients with T2DM who have inadequate glycaemic control while on insulin.MethodsThe cost effectiveness of dapagliflozin was estimated using the Cardiff Diabetes Model, using direct comparative efficacy data from a randomized placebo-controlled trial (ClinicalTrials.gov identifier NCT00673231). In this trial, up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk factor progression and the occurrence of future vascular events were estimated using the United Kingdom Prospective Diabetes Study\u00a068 risk equations. Costs and utilities were derived from the literature. The analysis was conducted from the societal perspective, simulating the remaining lifetime of the patients.ResultsThe overall incidence of macro- and microvascular complications was lower, and life expectancy was greater (19.43 versus 19.35\u00a0life-years [LYs]) in patients receiving dapagliflozin than in those not receiving dapagliflozin. Patients in the dapagliflozin arm obtained an incremental benefit of 0.42 quality-adjusted life-years (QALYs). The lifetime incremental cost per patient in the dapagliflozin arm was \u20ac2,293, resulting in an incremental cost-effectiveness ratio of \u20ac27,779 per LY gained and an incremental cost\u2013utility ratio of \u20ac5,502 per QALY gained. Sensitivity and scenario analyses showed that the results were insensitive to variations in modelling assumptions and input variables.ConclusionDapagliflozin in combination with insulin was estimated to be a cost-effective treatment option for patients with T2DM whose insulin treatment regimen does not provide adequate glycaemic control in a Dutch healthcare setting.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40261-013-0155-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "inadequate glycaemic control", 
      "glycaemic control", 
      "United Kingdom Prospective Diabetes Study", 
      "selective sodium-glucose cotransporter", 
      "randomized placebo-controlled trial", 
      "risk factor progression", 
      "incremental cost-effectiveness ratio", 
      "cost-effective treatment option", 
      "insulin treatment regimen", 
      "adequate glycaemic control", 
      "placebo-controlled trial", 
      "glycated hemoglobin levels", 
      "future vascular events", 
      "comparative efficacy data", 
      "incremental cost-utility ratio", 
      "lifetime incremental cost", 
      "titration of insulin", 
      "sodium-glucose cotransporter", 
      "cost-effectiveness ratio", 
      "cost-utility ratio", 
      "Cardiff Diabetes Model", 
      "cost effectiveness", 
      "Dutch healthcare setting", 
      "glycaemic imbalance", 
      "glycaemic targets", 
      "microvascular complications", 
      "vascular events", 
      "insulin therapy", 
      "diabetes mellitus", 
      "hemoglobin levels", 
      "overall incidence", 
      "treatment regimen", 
      "clinical evidence", 
      "Diabetes Study", 
      "treatment options", 
      "efficacy data", 
      "diabetes model", 
      "Dutch guidelines", 
      "cost utility", 
      "patients", 
      "dapagliflozin", 
      "risk equations", 
      "type 2", 
      "societal perspective", 
      "healthcare settings", 
      "insulin", 
      "incremental cost", 
      "incremental benefit", 
      "life expectancy", 
      "mellitus", 
      "T2DM", 
      "trials", 
      "such cases", 
      "ConclusionDapagliflozin", 
      "regimen", 
      "complications", 
      "therapy", 
      "arm", 
      "QALY", 
      "incidence", 
      "control", 
      "bodyweight", 
      "progression", 
      "treatment", 
      "cotransporter", 
      "cases", 
      "expectancy", 
      "guidelines", 
      "utility", 
      "options", 
      "setting", 
      "evidence", 
      "imbalance", 
      "effectiveness", 
      "target", 
      "levels", 
      "study", 
      "background", 
      "benefits", 
      "ratio", 
      "sensitivity", 
      "occurrence", 
      "events", 
      "analysis", 
      "Netherlands", 
      "need", 
      "practice", 
      "combination", 
      "Lys", 
      "literature", 
      "data", 
      "variables", 
      "types", 
      "results", 
      "titration", 
      "cost", 
      "model", 
      "perspective", 
      "macro", 
      "scenario analysis", 
      "variation", 
      "lifetime", 
      "assumption", 
      "input variables", 
      "equations", 
      "ObjectiveMany patients", 
      "MethodsThe cost effectiveness", 
      "direct comparative efficacy data", 
      "severe glycaemic imbalance", 
      "factor progression", 
      "Kingdom Prospective Diabetes Study", 
      "Prospective Diabetes Study", 
      "dapagliflozin arm"
    ], 
    "name": "Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands", 
    "pagination": "135-146", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051450610"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-013-0155-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24243529"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-013-0155-0", 
      "https://app.dimensions.ai/details/publication/pub.1051450610"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_606.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40261-013-0155-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0155-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0155-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0155-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0155-0'


 

This table displays all metadata directly associated to this object as RDF triples.

313 TRIPLES      22 PREDICATES      161 URIs      147 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-013-0155-0 schema:about N134feab558174b47a64b571d542c0db0
2 N19ba253a058f4f6ba9b277737100d8f7
3 N3c6aa91c838547a09675a8b5bd1421de
4 N4881b52295df43ef898daa2bb05a10e6
5 N4e678da032c74215a98cc992f6221551
6 N54159377ce3342fd961b89fc53cfe260
7 N57917e10954e4e77b4a00742986675cf
8 N60313d7f08d842a48c6fb81adc993f2f
9 N646aca622e154bb0bd64a083446e5df4
10 N6889c642791c4f17a440e7f2751e5196
11 N7e71d5d2a78b4710a023b24a2be3a1be
12 Naf2c5a3c03d648f5aae6358d865f553a
13 Nc18ea17d2b754ce8a07b7e60b68a5963
14 Ndab56e1539ef48299042b566c562732a
15 Ned431dec545c49c4a6a67362c1f6a2fc
16 Nfe29814ba88b4577b7d7eeb0462f47a6
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N8fa0e656d4984cd5b2c3734c8858f8f3
20 schema:citation sg:pub.10.1007/s00125-004-1527-z
21 sg:pub.10.1007/s10198-010-0261-3
22 sg:pub.10.1007/s10926-011-9317-1
23 sg:pub.10.1186/1475-2840-7-24
24 sg:pub.10.1186/1478-7547-8-21
25 sg:pub.10.2165/11597060-000000000-00000
26 schema:datePublished 2013-11-16
27 schema:datePublishedReg 2013-11-16
28 schema:description Background and ObjectiveMany patients with type 2 diabetes mellitus (T2DM) on insulin therapy have inadequate glycaemic control. In such cases, Dutch guidelines recommend unlimited up-titration of insulin, yet in practice many patients never reach their glycaemic target. Clinical evidence shows that dapagliflozin—a highly selective sodium–glucose cotransporter 2 inhibitor—meets a need for these patients, i.e. by reducing glycated haemoglobin levels and bodyweight. We estimated the cost effectiveness and cost utility of adding dapagliflozin to insulin compared with not adding dapagliflozin in patients with T2DM who have inadequate glycaemic control while on insulin.MethodsThe cost effectiveness of dapagliflozin was estimated using the Cardiff Diabetes Model, using direct comparative efficacy data from a randomized placebo-controlled trial (ClinicalTrials.gov identifier NCT00673231). In this trial, up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk factor progression and the occurrence of future vascular events were estimated using the United Kingdom Prospective Diabetes Study 68 risk equations. Costs and utilities were derived from the literature. The analysis was conducted from the societal perspective, simulating the remaining lifetime of the patients.ResultsThe overall incidence of macro- and microvascular complications was lower, and life expectancy was greater (19.43 versus 19.35 life-years [LYs]) in patients receiving dapagliflozin than in those not receiving dapagliflozin. Patients in the dapagliflozin arm obtained an incremental benefit of 0.42 quality-adjusted life-years (QALYs). The lifetime incremental cost per patient in the dapagliflozin arm was €2,293, resulting in an incremental cost-effectiveness ratio of €27,779 per LY gained and an incremental cost–utility ratio of €5,502 per QALY gained. Sensitivity and scenario analyses showed that the results were insensitive to variations in modelling assumptions and input variables.ConclusionDapagliflozin in combination with insulin was estimated to be a cost-effective treatment option for patients with T2DM whose insulin treatment regimen does not provide adequate glycaemic control in a Dutch healthcare setting.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N795dbbfb03de43ccaf4676a9cbdca267
33 Nd9aab79ceeaf4d3bb341125dd0700b9c
34 sg:journal.1100199
35 schema:keywords Cardiff Diabetes Model
36 ConclusionDapagliflozin
37 Diabetes Study
38 Dutch guidelines
39 Dutch healthcare setting
40 Kingdom Prospective Diabetes Study
41 Lys
42 MethodsThe cost effectiveness
43 Netherlands
44 ObjectiveMany patients
45 Prospective Diabetes Study
46 QALY
47 T2DM
48 United Kingdom Prospective Diabetes Study
49 adequate glycaemic control
50 analysis
51 arm
52 assumption
53 background
54 benefits
55 bodyweight
56 cases
57 clinical evidence
58 combination
59 comparative efficacy data
60 complications
61 control
62 cost
63 cost effectiveness
64 cost utility
65 cost-effective treatment option
66 cost-effectiveness ratio
67 cost-utility ratio
68 cotransporter
69 dapagliflozin
70 dapagliflozin arm
71 data
72 diabetes mellitus
73 diabetes model
74 direct comparative efficacy data
75 effectiveness
76 efficacy data
77 equations
78 events
79 evidence
80 expectancy
81 factor progression
82 future vascular events
83 glycaemic control
84 glycaemic imbalance
85 glycaemic targets
86 glycated hemoglobin levels
87 guidelines
88 healthcare settings
89 hemoglobin levels
90 imbalance
91 inadequate glycaemic control
92 incidence
93 incremental benefit
94 incremental cost
95 incremental cost-effectiveness ratio
96 incremental cost-utility ratio
97 input variables
98 insulin
99 insulin therapy
100 insulin treatment regimen
101 levels
102 life expectancy
103 lifetime
104 lifetime incremental cost
105 literature
106 macro
107 mellitus
108 microvascular complications
109 model
110 need
111 occurrence
112 options
113 overall incidence
114 patients
115 perspective
116 placebo-controlled trial
117 practice
118 progression
119 randomized placebo-controlled trial
120 ratio
121 regimen
122 results
123 risk equations
124 risk factor progression
125 scenario analysis
126 selective sodium-glucose cotransporter
127 sensitivity
128 setting
129 severe glycaemic imbalance
130 societal perspective
131 sodium-glucose cotransporter
132 study
133 such cases
134 target
135 therapy
136 titration
137 titration of insulin
138 treatment
139 treatment options
140 treatment regimen
141 trials
142 type 2
143 types
144 utility
145 variables
146 variation
147 vascular events
148 schema:name Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
149 schema:pagination 135-146
150 schema:productId N0f1a344044304fcb866e0316d5e59265
151 N1bcaa3d2356a479bbcc6b759c84844df
152 N67c67240aa3c420abdcd6dafc493b4f1
153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051450610
154 https://doi.org/10.1007/s40261-013-0155-0
155 schema:sdDatePublished 2021-11-01T18:21
156 schema:sdLicense https://scigraph.springernature.com/explorer/license/
157 schema:sdPublisher Nf98b46529c124ae0ba9b600001d8e24a
158 schema:url https://doi.org/10.1007/s40261-013-0155-0
159 sgo:license sg:explorer/license/
160 sgo:sdDataset articles
161 rdf:type schema:ScholarlyArticle
162 N0f1a344044304fcb866e0316d5e59265 schema:name dimensions_id
163 schema:value pub.1051450610
164 rdf:type schema:PropertyValue
165 N134feab558174b47a64b571d542c0db0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Benzhydryl Compounds
167 rdf:type schema:DefinedTerm
168 N19ba253a058f4f6ba9b277737100d8f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Diabetes Mellitus, Type 2
170 rdf:type schema:DefinedTerm
171 N1bcaa3d2356a479bbcc6b759c84844df schema:name pubmed_id
172 schema:value 24243529
173 rdf:type schema:PropertyValue
174 N32e27d906cf542ac9fd291ec54d659db rdf:first sg:person.01365107104.86
175 rdf:rest rdf:nil
176 N3c6aa91c838547a09675a8b5bd1421de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Glucosides
178 rdf:type schema:DefinedTerm
179 N4881b52295df43ef898daa2bb05a10e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Female
181 rdf:type schema:DefinedTerm
182 N4e678da032c74215a98cc992f6221551 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Practice Guidelines as Topic
184 rdf:type schema:DefinedTerm
185 N54159377ce3342fd961b89fc53cfe260 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Netherlands
187 rdf:type schema:DefinedTerm
188 N57917e10954e4e77b4a00742986675cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Quality-Adjusted Life Years
190 rdf:type schema:DefinedTerm
191 N5810a33db5f644afb2ea069ff6ed248e rdf:first sg:person.0700022153.26
192 rdf:rest Ne6ee52143b4e485d830295d224c35f0c
193 N60313d7f08d842a48c6fb81adc993f2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Aged
195 rdf:type schema:DefinedTerm
196 N646aca622e154bb0bd64a083446e5df4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Drug Therapy, Combination
198 rdf:type schema:DefinedTerm
199 N67c67240aa3c420abdcd6dafc493b4f1 schema:name doi
200 schema:value 10.1007/s40261-013-0155-0
201 rdf:type schema:PropertyValue
202 N6889c642791c4f17a440e7f2751e5196 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Severity of Illness Index
204 rdf:type schema:DefinedTerm
205 N795dbbfb03de43ccaf4676a9cbdca267 schema:issueNumber 2
206 rdf:type schema:PublicationIssue
207 N7e71d5d2a78b4710a023b24a2be3a1be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Male
209 rdf:type schema:DefinedTerm
210 N8fa0e656d4984cd5b2c3734c8858f8f3 rdf:first sg:person.07407076240.42
211 rdf:rest Na0d8564c44664c4b894c1a38ce31ca47
212 Na0d8564c44664c4b894c1a38ce31ca47 rdf:first sg:person.0715210142.64
213 rdf:rest N5810a33db5f644afb2ea069ff6ed248e
214 Naf2c5a3c03d648f5aae6358d865f553a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Insulin
216 rdf:type schema:DefinedTerm
217 Nc18ea17d2b754ce8a07b7e60b68a5963 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Middle Aged
219 rdf:type schema:DefinedTerm
220 Nd9aab79ceeaf4d3bb341125dd0700b9c schema:volumeNumber 34
221 rdf:type schema:PublicationVolume
222 Ndab56e1539ef48299042b566c562732a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Cost-Benefit Analysis
224 rdf:type schema:DefinedTerm
225 Ndfbd04fc1bee441ea2433e8541b7fadd rdf:first sg:person.01270616201.88
226 rdf:rest N32e27d906cf542ac9fd291ec54d659db
227 Ne6ee52143b4e485d830295d224c35f0c rdf:first sg:person.01346767345.38
228 rdf:rest Ndfbd04fc1bee441ea2433e8541b7fadd
229 Ned431dec545c49c4a6a67362c1f6a2fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Humans
231 rdf:type schema:DefinedTerm
232 Nf98b46529c124ae0ba9b600001d8e24a schema:name Springer Nature - SN SciGraph project
233 rdf:type schema:Organization
234 Nfe29814ba88b4577b7d7eeb0462f47a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Hypoglycemic Agents
236 rdf:type schema:DefinedTerm
237 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
238 schema:name Medical and Health Sciences
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
241 schema:name Clinical Sciences
242 rdf:type schema:DefinedTerm
243 sg:journal.1100199 schema:issn 1173-2563
244 1179-1918
245 schema:name Clinical Drug Investigation
246 schema:publisher Springer Nature
247 rdf:type schema:Periodical
248 sg:person.01270616201.88 schema:affiliation grid-institutes:None
249 schema:familyName Townsend
250 schema:givenName Rebecca
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270616201.88
252 rdf:type schema:Person
253 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.4827.9
254 schema:familyName McEwan
255 schema:givenName Phil
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
257 rdf:type schema:Person
258 sg:person.01365107104.86 schema:affiliation grid-institutes:grid.481843.2
259 schema:familyName Roudaut
260 schema:givenName Marina
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365107104.86
262 rdf:type schema:Person
263 sg:person.0700022153.26 schema:affiliation grid-institutes:grid.418151.8
264 schema:familyName Bergenheim
265 schema:givenName Klas
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700022153.26
267 rdf:type schema:Person
268 sg:person.0715210142.64 schema:affiliation grid-institutes:grid.491222.e
269 schema:familyName Pompen
270 schema:givenName Marjolein
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715210142.64
272 rdf:type schema:Person
273 sg:person.07407076240.42 schema:affiliation grid-institutes:None
274 schema:familyName van Haalen
275 schema:givenName Heleen G. M.
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07407076240.42
277 rdf:type schema:Person
278 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
279 https://doi.org/10.1007/s00125-004-1527-z
280 rdf:type schema:CreativeWork
281 sg:pub.10.1007/s10198-010-0261-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020769088
282 https://doi.org/10.1007/s10198-010-0261-3
283 rdf:type schema:CreativeWork
284 sg:pub.10.1007/s10926-011-9317-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001967775
285 https://doi.org/10.1007/s10926-011-9317-1
286 rdf:type schema:CreativeWork
287 sg:pub.10.1186/1475-2840-7-24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052715065
288 https://doi.org/10.1186/1475-2840-7-24
289 rdf:type schema:CreativeWork
290 sg:pub.10.1186/1478-7547-8-21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021046231
291 https://doi.org/10.1186/1478-7547-8-21
292 rdf:type schema:CreativeWork
293 sg:pub.10.2165/11597060-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033801058
294 https://doi.org/10.2165/11597060-000000000-00000
295 rdf:type schema:CreativeWork
296 grid-institutes:None schema:alternateName AstraZeneca, Brussels, Belgium
297 Health Economics, AstraZeneca BV, P.O. Box 599, 2700 AN, Zoetermeer, The Netherlands
298 schema:name AstraZeneca, Brussels, Belgium
299 Health Economics, AstraZeneca BV, P.O. Box 599, 2700 AN, Zoetermeer, The Netherlands
300 rdf:type schema:Organization
301 grid-institutes:grid.418151.8 schema:alternateName AstraZeneca, Mölndal, Sweden
302 schema:name AstraZeneca, Mölndal, Sweden
303 rdf:type schema:Organization
304 grid-institutes:grid.481843.2 schema:alternateName Health Economics and Outcome Research, Bristol-Myers Squibb, Rueil-Malmaison, France
305 schema:name Health Economics and Outcome Research, Bristol-Myers Squibb, Rueil-Malmaison, France
306 rdf:type schema:Organization
307 grid-institutes:grid.4827.9 schema:alternateName Centre for Health Economics, Swansea University, Swansea, UK
308 schema:name Centre for Health Economics, Swansea University, Swansea, UK
309 HEOR Ltd, Monmouth, UK
310 rdf:type schema:Organization
311 grid-institutes:grid.491222.e schema:alternateName Bristol-Myers Squibb, Woerden, The Netherlands
312 schema:name Bristol-Myers Squibb, Woerden, The Netherlands
313 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...